Authors
Mahdis Nabipour, Charlotte Hagen Skadhauge, Line Juel Rasmussen, Hans Bräuner-Osborne, Jesper M Mathiesen, Anders A Jensen
Published in
Basic & clinical pharmacology & toxicology. Volume 139. Issue 6.
Abstract
We previously developed nanobodies acting as positive allosteric modulators (PAMs) of the calcium-sensing receptor (CaSR). Here, we sought to develop more potent CaSR modulators by creating bivalent nanobody constructs using 'tail-to-head' peptide-linker conjugation. The constructs were functionally characterized at CaSR in HEK293 cells in a Ca2+ mobilization assay. Homobivalent Nb4-Nb4 and Nb10-Nb10 constructs with linkers comprising 3, 5, 6 or 9 GGGG(S/T) repeats all displayed CaSR PAM potencies comparable with those exhibited by their monovalent counterparts. Likewise, five heterobivalent nanobodies combining Nb4, Nb10, Nb11, Nb36 or Nb37 through [GGGG(S/T)]9 linkers exhibited PAM potencies similar to that of the monovalent version of the first (N-terminal) nanobody in the respective constructs. This prompted us to examine the functional properties of [GGGG(S/T)]9-linked constructs combining Nb4 and the mGluR5-selective nanobody PAM Nb43mGlu5. Nb4-L9-Nb43mGlu5 displayed slightly increased CaSR PAM potency relative to Nb4, whereas Nb43mGlu5-L9-Nb4 exhibited ~40- and ~10-fold reduced potency compared with Nb4-L9-Nb43mGlu5 and Nb4, respectively. The findings indicate that 'tail-to-head' conjugation markedly reduces CaSR binding affinity of the second (C-terminal) nanobody and likely explains the lack of synergistic enhancement of PAM potency in the bivalent constructs. Thus, the suitability of tail-to-head linker conjugation of nanobodies is context dependent, governed by how the nanobody engages its target and by whether the linker perturbs these interactions.
PMID:
42951375
Bibliographic data and abstract were imported from PubMed on 29 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0